OREX-1038: a potential new treatment for pain with low abuse liability and limited adverse effects
Lisa R. Gerak(The University of Texas at San Antonio Health Science Center), Peter Flynn(Nepean Hospital), Barbara Belli, Lisette M. Acevedo(VistaGen Therapeutics (United States)), Keith M. Olson(University of Michigan), Charles P. France(The University of Texas at San Antonio Health Science Center), David R. Maguire(The University of Texas at San Antonio Health Science Center), Stephen M. Husbands(University of Bath), Gerta Cami‐Kobeci(University of Bedfordshire), John R. Traynor(University of Michigan)
Cited by 4
Related Papers
VEGF-Induced Vascular Permeability Is Mediated by FAK
|Developmental Cell|2012|339
Studies Leading to Potent, Dual Inhibitors of Bcl-2 and Bcl-xL
|Journal of Medicinal Chemistry|2007|295
The novel μ‐opioid receptor agonist PZM21 depresses respiration and induces tolerance to antinociception
|British Journal of Pharmacology|2018|174
Endogenous RGS Protein Action Modulates μ-Opioid Signaling through Gαo
|Journal of Biological Chemistry|2003|107